This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
December 07, 2022
Oncopeptides provides update on Pepaxto US marketing authorization
December 05, 2022
Vicore announces first patient enrolled in COMPANION; a digital therapeutic pivotal study for patients with pulmonary fibrosis
November 30, 2022
Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema
November 25, 2022
Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank
November 14, 2022
Priothera – Positive mocravimod Phase 1b clinical data published in Transplantation and Cellular Therapy
November 11, 2022
Oncopeptides’ Pepaxti has been granted marketing authorization in the UK
November 10, 2022
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
November 10, 2022
Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement
November 09, 2022
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
November 09, 2022
Oncopeptides announces the market potential for Pepaxti in Europe